Publications by authors named "Eduardo Martinez-Diaz"
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1-2 Clinical Trial.
Gilda Lemos-Pérez Yinet Barrese-Pérez Yahima Chacón-Quintero Rolando Uranga-Piña Yisel Avila-Albuerne
Vaccines (Basel)
September 2024
Article Synopsis
- * The study found that both vaccines had no severe adverse effects and a high percentage of participants showed increased antibody responses after receiving the booster, with 83.3% for Abdala in Phase 1 and 88.6% in Phase 2.
- * Both vaccines exceeded the immunogenicity goals set by the trial, with significant increases in antibody levels and neutralizing capacity against SARS-CoV-2 variants after the booster dose, indicating strong efficacy.
Article Synopsis
- Developing affordable SARS-CoV-2 vaccines is crucial for global vaccination efforts and controlling COVID-19, with a focus on using the receptor-binding domain (RBD) produced in yeast.
- The RBD was modified to enhance protein interactions and purification, yielding a high quantity of correctly folded protein that showed strong reactions with antibodies from recovered patients and vaccinated individuals.
- Animal studies demonstrated that the RBD vaccine induced significant immune responses, suggesting it is a promising candidate for COVID-19 immunization.